Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Clinical overview of metronomic chemotherapy in breast cancer

(2015) Elisabetta Munzone et al.   Nature Reviews Clinical Oncology

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

(2015) Roberto Salgado et al.   JAMA Oncology

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

(2012) F. Andre et al.   CLINICAL CANCER RESEARCH

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

(2009) Vedran Radojcic et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune infiltration in human tumors: a prognostic factor that should not be ignored

(2009) F Pagès et al.   ONCOGENE

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION